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Abstract
MicroRNAs (miRNAs) are small‐sized RNAs with ability to regulate gene expression 
and have been recently discovered as promising diagnostic and therapeutic biomarkers 
in the field of clinical medicine and microbiology, specifically in viral diseases. Infections 
with hepatitis B virus (HBV) or hepatitis C virus (HCV) often lead to chronic infections 
and development of liver hepatocellular carcinoma (HCC). Challenges in early diag‐
nosis of HCC and rapid development of novel HCV antivirals call for identification of 
novel miRNA biomarkers. An extensive selection of single miRNAs and miRNA pan‐
els has been provided by accumulating studies, discovering miRNA potentials in HBV 
and HCV diagnostics and treatment. Currently, the diagnostic potential of miRNAs in 
HBV and HCV has not been established yet. However, a promising HCV treatment drug 
Miravirsen, a locked nucleic acid, complementary to miRNA‐122, has entered a human 
clinical trial recently. In this review, we outline the role of miRNAs in HBV and HCV 
pathogenesis and differences in up‐ and downregulation of miRNAs upon HBV and 
HCV infection and HCC development.
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1. Introduction
Hepatitis B and C viruses (HBV and HCV) are globally spread hepatotropic pathogens and 
major etiological factors of liver cirrhosis and hepatocellular carcinoma (HCC), infecting mil‐
lions of people worldwide. HBV and HCV significantly differ in structure, genomic charac‐
teristics, and pathogenesis [1, 2].
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
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MicroRNAs (miRNAs) are small noncoding RNAs that control gene expression and par‐
ticipate in complex cellular pathways and pathogenesis of various viral infections and 
cancers [3–5].
Despite the availability of prophylactic HBV vaccine and recently improved HCV therapy 
strategies, early diagnosis of HBV/HCV‐related HCC, viral reactivation, resistance, drug 
interactions, and viral interferences in HBV/HCV co‐infected patients remain major obstacles 
in currently available HBV and HCV diagnostics and treatments [6, 7].
Multiple studies have proposed specific miRNA or miRNA panels to be used as biomarkers 
for HBV/HCV‐related liver disease, staging of liver disease progression, and anti‐HBV/HCV 
therapeutic options.
In this chapter, we briefly outline the HBV and HCV biology and basis of miRNA expression 
in liver and HCC. Subsequently, we summarize recently described and proposed miRNAs for 
HBV‐ and HCV‐associated diagnostics, particularly HBV/HCV‐related HCC.
2. Hepatitis B virus
Hepatitis B virus is an enveloped, partially double‐stranded DNA virus, classified in the 
Hepadnaviridae family. HBV genome is approximately 3.2 kb long and contains four RNA 
transcripts (P, S, C, and X), of which the S transcript encodes the surface antigen HBsAg, 
the main indicator of HBV infection [1]. Upon infection, cellular polymerase converts HBV 
DNA into covalently closed circular DNA (cccDNA), which represents a constant template 
for pregenomic RNA and mRNA transcription. Due to the stable state of HBV cccDNA in 
hepatocytes, HBV can reactivate after immunosuppression [1, 8].
HBV is classified into eight genotypes (designated A through H). Most chronic infections are 
related to infection with HBV genotypes B and C; however, in Europe, genotype D has been 
shown to be more often associated with active liver disease [1].
Globally, two billion people are infected with HBV, with majority of HBV infections occur‐
ring in South‐Eastern Asia and sub‐Saharan Africa [9, 10]. Approximately, one‐fourth of 
HBV‐infected individuals suffer from liver cirrhosis and 70–90% of HCC develop from cir‐
rhotic liver [1, 10]. In developing countries, HBV infection accounts for about 60% of the 
total liver cancer and in developed countries for about 23% [11]. In endemic areas, HBV 
infections occur mostly by vertical and perinatal transmission and in more than 90% lead to 
chronic HBV infections. In low prevalence countries, HBV infections occur mostly through a 
horizontal transfer (sexual transmission), which in more than 90% lead to acute HBV infec‐
tions with spontaneous viral clearance [10]. Despite improved HBV antiviral therapy over 
the past two decades, and the prophylactic anti‐HBV vaccine, available since 1981, prena‐
tal maternal HBeAg seropositivity in endemic countries remains significantly connected to 
HCC and elimination of cccDNA remains the major challenge in HBV‐related treatment 
strategies [1, 12, 13].
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3. Hepatitis C virus
Hepatitis C virus has a positive‐sense single‐stranded RNA genome of approximate length 
of 9.6 kb and is classified in the family Flaviviridae. The HCV genome encodes a polyprotein 
that is cleaved into three structural and seven nonstructural proteins. Based on HCV genomic 
sequence diversity, HCV is classified into seven genotypes and more than 60 subtypes are 
identified [2, 14]. Genotypes 1, 2, and 3 are globally distributed and cause most of HCV infec‐
tions in North America and Europe. In Middle East and North and Central Africa, genotype 4 
prevails generally, in South Africa genotype 5, in Asia genotype 6, while a recently discovered 
genotype 7 originates from Central Africa [2, 15].
Currently, no vaccine is available for the prevention of HCV infection. Most HCV transmis‐
sions occur by intravenous drug abuse, sexual transmission, and occupational exposure to 
HCV‐infected blood [2]. Potential long‐term outcomes in chronically HCV‐infected people 
are liver cirrhosis and HCC, which remain the leading cause for liver transplantation. HCV 
is globally infecting over 150 million individuals [16–18]. Recent estimate on global anti‐HCV 
prevalence is 115 million‐infected individuals, of whom 80 million are actively viremic [19].
A recent study by Sibley et al. [20] forecasted changes in HCV‐related disease up to 2030 
and concluded that HCV‐related morbidity and mortality are estimated to increase due to an 
aging of the HCV‐infected population and currently available treatment will be inadequate if 
reductions in HCV‐related disease of this magnitude are to be achieved [20].
4. MicroRNAs
Micro‐ribonucleic acids (microRNAs/miRNAs) are noncoding RNAs of 18–25 nucleotides in 
length that complementarily target the 3′‐untranslated regions (3′ UTRs), or less commonly 
5′‐untranslated regions (5′ UTRs) of messenger RNAs (mRNAs) [3]. Genes encoding miRNAs 
are located in intragenic regions or introns of mRNAs or noncoding RNAs [21]. MiRNAs are 
transcribed from the genome by the RNA polymerase II into primary‐miRNA (pri‐miRNA) 
hairpins, which are processed by Drosha (class III RNase) into pre‐miRNAs. Pre‐miRNAs are 
exported from the nucleus to the cytoplasm, where they are processed by a second RNaseIII 
Dicer into short double‐stranded mature miRNAs, consisting of 5’ and 3’ arms. Finally, single‐
stranded miRNAs are assembled with specific proteins and form a RNA‐induced‐silencing 
complex (RISC). At least two to seven nucleotide complementarities with the target sequence 
are required for RISC‐mediated target silencing [22–24].
The binding of miRNAs in posttranscriptional or translational level provides a rapid and 
sensitive mechanism of gene expression regulation, either by suppressing the translation of 
mRNA or by promoting mRNA degradation [25]. Gene silencing by a full complementary 
miRNA sequence directs cleavage of the target mRNA, while partial complementary miRNA 
sequence suppresses mRNA translation [26, 27]. Currently, more than 2,588 mature miRNAs 
are reported in a human genome [28, 29] and due to sufficient partial complementarity to 
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the target sequence it has been shown that one type of miRNA could affect up to 200 genes, 
and over a 100 different targets can be involved in approximately 100 different biochemical 
pathways [30, 31].
4.1. MiRNAs mechanism
MiRNAs are participating in various cellular processes such as cell development, differen‐
tiation, proliferation, metabolism, immune responses, apoptosis, and oncogenesis [32, 33]. 
Estimates in humans suggest that 60–70% of all genes are regulated by miRNAs [4]. Being 
involved in numerous biological pathways, their expression and regulation reflect in various 
diseases, stages of the particular disease, especially in cancer development [34, 35].
MiRNAs are cell‐free‐circulating molecules that can be detected in almost every body fluid. 
Their high stability and accessibility make them ideal noninvasive markers for the early 
diagnosis of different pathophysiological processes. Indeed, a large amount of evidence sug‐
gests that miRNA profiles could provide a classification system for various tumors, as well 
as an important tool for the diagnosis and treatment of cancer and viral diseases [36–41]. 
Accordingly, cellular miRNAs have an ability to regulate pathogenesis of viral infections, and 
at the same time viruses manipulate with host cellular machinery, including miRNAs [42, 43].
Increased interest in hepatitis B and hepatitis C disease pathogenesis and diagnostics has lead 
to the emergence of various studies over the last 15 years that have tried to evaluate plasma 
and tissue levels of miRNAs in order to provide or improve the diagnosis of HBV and HCV 
infections as well as HBV‐ and HCV‐related HCC [5].
5. MiRNAs in normal liver
Liver consists of various cell types, mainly divided in the parenchymal cells (hepatocytes) 
and non‐parenchymal cells (biliary epithelial cells and lymphoid cells, etc.). Each cell type 
expresses its unique miRNA profile. While miRNAs are up‐ or downregulated in almost 
every stage of hepatic development, they accelerate or inhibit liver proliferation and play the 
major role in regulation of diverse liver functions [44]. It has been shown that a total of 277 
miRNAs are expressed in the liver, with miR‐122 being one of the most abundant and liver‐
specific miRNAs [45, 46]. Besides miR‐192, miR‐199a/b‐3p, miR‐101, miR‐99a, and let‐7a/b/c/f 
(let‐7 family), which account for 80% of the total miRNA in liver, miR‐122 accounts for 70% 
of the total liver miRNAs [45, 47]. Expression of miRNAs in the normal liver has been estab‐
lished by microarray systems and library sequencing [47–49].
5.1. Function of miRNAs in normal liver
The function of miR‐122 has been explored in a variety of in vivo studies, including the miR‐122 
gene knockdown or silencing of miR‐122 with antagomirs [50–52]. In the miR‐122 gene knock‐
down mice, it has been shown that the deletion of the miR‐122 gene resulted in hepatosteato‐
sis, hepatitis, and the development of liver tumors [52]. Beyond that, studies implicate miR‐122 
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as a key regulator of cholesterol and fatty‐acid metabolism [50]. However, results of studies 
evaluating up‐ and downregulated miRNA profiles in differentiating liver cells are not con‐
sistent. Besides various technical issues, including differences in clinical samples and different 
miRNA matrices in miRNA assays, different degrees of miRNA expression among studies 
suggest that the miRNA profile is also influenced by the origin of the progenitor cell and that 
it is difficult to compare miRNA profiles in different cellular developmental stages [53].
However, it has been shown in two studies by Liu et al. [54] and Tzur et al. [55] that embry‐
onic liver mainly contains miRNAs‐122, ‐192, ‐194, ‐451, and ‐483‐3p, whereas miR‐122 can be 
detected in embryonic stem cells as well as in hepatocytes and continues to be expressed in the 
adulthood. Studies of hepatic malignancy pathologies have shown that miRNAs have specific 
targets in specific disease states [44, 53, 56]. Interestingly, a biphasic pattern of miRNA expres‐
sion was observed in rats after liver surgical resection [57]. In the first 18 h after hepatectomy, 
about 40% of miRNAs were upregulated, whereas by 24 h there was a negative feedback 
mechanism which downregulated about 70% of all miRNAs [57]. These negative feedback 
loops are postulated to play an important role in liver regeneration processes, required for 
recovery of liver cells after injury; however, the abundance of miRNAs does not directly cor‐
relate with the predictable role of specific cells.
Since essential knowledge on liver regeneration processes has been delivered from rodent 
model studies, further studies are warranted to confirm post‐hepatectomy miRNA level 
changes in humans [4, 57]. Investigation of miRNA levels in specific stages of liver organo‐
genesis may reveal potential biomarkers for liver disease states.
6. miRNA and HBV‐ and HCV‐related liver disease
HCC is the fifth most common cancer worldwide. Deregulation of miRNA expression could 
be one of the key factors in the development of liver pathology, including viral hepatitis and 
HCC [11]. Evidence is rapidly growing that specific miRNAs could be used as potential bio‐
markers for HCC, tumor progression, and response to therapeutic targets [4].
Infection with HBV and HCV can lead to chronic hepatitis, liver cirrhosis, or even HCC. 
Approximately 50–80% of HCC cases are associated with chronic HBV or HCV infection 
[10]. In the past several years, the involvement of miRNA in the pathogenesis of HBV‐/HCV‐
related liver diseases has been well documented [53]. Since miRNAs can be directly involved 
in antiviral immune‐pathological events, it is inevitable that miRNA target sequences in viral 
populations remained conserved, providing relevant evidence of the biological significance 
of potential miRNA‐based antiviral interventions [58]. For the time being, no HBV‐ or HCV‐
encoded miRNAs have been reported. Using computational approaches, one candidate HBV 
miRNA has been found but its function remains undetermined [59].
It should be noted that miRNA dysregulation has been studied in various experimental 
settings, mainly involving in vitro systems, HBV‐/HCV‐replication‐supporting cell lines, 
transgenic mice, cultured hepatocytes (mouse/rat/human), circulating blood cells or serum 
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of HBV‐/HCV‐infected individuals, and liver tissue samples. MiRNA expression in model 
systems has been measured mainly with qualitative real time‐polymerase chain reactions 
(RT‐PCRs) and/or miRNA microarrays and less frequently with next‐generation sequencing 
(NGS) (for review, see [23, 60]).
6.1. MiRNAs and HBV infection
It is well known that numerous cellular miRNAs are able to promote or repress the HBV 
lifecycle, either by directly targeting HBV transcripts or by indirectly targeting cellular 
mediators, involved in the HBV pathogenesis. Alternatively, HBV infection dysregulates 
cellular miRNAs and in this manner controls the host gene expression to promote its rep‐
lication [60].
A variety of miRNAs have been reported in regulation of HBV replication namely miR‐122, 
let‐7 family, miR‐199 family, miR‐15 family, miR‐125 family, and miR‐17‐92 cluster (exten‐
sively reviewed in [60]). Reported effects of the most abundant liver miRNA, miR‐122, on 
HBV lifecycle remain mixed. Whereas some studies reported miRNAs as inhibitors of HBV 
replication [61–64], others have failed to even identify miR‐122 as a regulator of the HBV life‐
cycle [65]. For example, in a study by Qiu et al. [63], in comparison to the control system, co‐
transfection of Huh7 cells with miR‐122 inhibitor, and a plasmid encoding the HBV genome, 
the production of HBsAg and HBeAg increased, suggesting a negative regulatory effect of 
miR‐122 on HBV lifecycle.
The study of Wang et al. [64] reported downregulation of miR‐122 expression in liver of 
patients with HBV infection, in comparison to healthy controls, and showed that the miR‐122 
levels were negatively correlated with intrahepatic viral load and hepatic inflammation. 
Researchers concluded that HBV‐induced miR‐122 downregulation enhances HBV replica‐
tion through cyclin G1‐modulated P53 activity and that HBV mRNAs harboring complemen‐
tary sites to miR‐122 sequester miR‐122 and contribute to viral persistence and carcinogenesis 
[61, 64].
Guo et al. [66] showed that members of the miRs‐371‐372‐373 (miRs‐371‐3) gene cluster were 
co‐upregulated in HBV‐producing HepG2.2.15 cells and revealed that miRs‐372/373 pro‐
motes HBV expression by targeting the transcription factor NFIB. Furthermore, Zhang et al. 
[65] reported that miR‐1 promotes HBV replication, transcription, and antigen expression by 
indirect modulation of host genes expression in HCC cell line. In addition, they have shown 
that miR‐1 arrested cell cycle, inhibited proliferation, and therefore reversed the cancer cell 
phenotype, which is in contradiction with HBV‐induced carcinogenesis, since HBV infection 
promotes hepatocellular proliferation [65].
Jin et al. [67] have shown that downregulation of miR‐501 in HepG2.2.15 cells could signifi‐
cantly inhibit HBV replication, thus representing a potential therapeutic target. They sug‐
gested that miR‐501 promotes HBV replication through inhibition of the HBXIP, which 
interacts with HBx protein and normally represses HBV replication [67]. In a mouse model, 
Dai et al. [68] reported that miR‐15b promoted HBV replication by direct inhibition of hepa‐
tocyte nuclear factor HNF1α.
Advances in Treatment of Hepatitis C and B326
On the other hand, miR‐125 family members, miR‐125a and miR‐125b, have been reported to 
suppress the HBV lifecycle. In the PLC/PRF/5 cell line, miR‐125a‐5p was identified as a down‐
regulator of HBsAg expression by directly targeting HBV RNAs [69], while miR‐125b inhibited 
HBV in HepG2.2.15 cells [70]. The miR‐22 has been reported as a regulatory molecule which 
inhibits HBV infection [71]. Furthermore, miR‐199a‐3p and miR‐210 were shown to repress the 
HBV replication in HepG2.2.15 cells by directly targeting the HBV S protein‐coding region [72], 
while inhibition of miR‐20 and miR‐92a‐1 increased levels of HBV RNAs in HepAD38 hepa‐
toma cells [73]. Hu et al. [74] demonstrated that miR‐141 suppresses HBV replication by reduc‐
ing HBV promoter activities and two separate studies suggested upregulation of miR‐181a in 
HBV‐infected hepatoma cells, implying an important role in the development of HCC [75, 76].
6.2. MiRNAs and HCV infection
HCV lifecycle is influenced by host miRNAs in all stages: entry, translation, replication, and 
assembly [43]. As the HCV genome is single‐stranded RNA, it serves as a template for its rep‐
lication and direct binding site for host miRNAs. Among high number of miRNAs reported 
to be involved in the regulation of HCV infection and replication, most miRNAs have been 
documented to directly target the HCV genome: miR‐1, miR‐30, miR‐122, miR‐128, miR‐196, 
miR‐296, miR‐351, miR‐431, and miR‐448 [77, 78].
Microarray analysis on human hepatoma cells has revealed changed expression profiles 
of 108 human miRNAs after HCV infection [79]. Furthermore, Liu et al. [79] showed that 
after acute HCV infection, miR‐122 was downregulated, whereas miR‐296 and miR‐351 were 
significantly upregulated. In addition, it has been shown that HCV infection upregulated 
the expression of miR‐192, miR‐194, and miR‐215, whereas the expression of miR‐320 and 
miR‐491 was downregulated [80]. It was reported that miR‐192/miR‐215 and miR‐491 could 
enhance HCV replication [80].
For the most abundant miRNA in the liver, miR‐122, it has been demonstrated that it pro‐
motes HCV replication by direct binding to the less commonly used UTR‐binding site, the 
5′ UTR site of the HCV RNA, which leads to Argonaute (Ago) protein complex recruitment, 
stabilization of the viral RNA, and activation of the RNA translation [77, 81, 82]. In vitro stud‐
ies have shown that miR‐122 is essential for HCV replication [81].
On the other hand, it has been shown that miR‐122 exhibits anti‐inflammatory and anti‐
tumorigenic properties in mice knockdown studies [52]. Mixed results exist on expression 
levels of miR‐122 and development of HCC‐ or HCV‐induced HCC. Coulouarn et al. [83] have 
shown that the loss of miR‐122 expression in liver cancer correlated with HCC progression, 
whereas in another study, the upregulation of miR‐122 promoted the HCV‐related HCC [84].
The increased expression of miR‐155 in HCV‐infected patients promotes hepatocarcinogenesis 
and inhibits apoptosis of hepatocytes [85]. Furthermore, the direct effect on HCV replication 
cycle has been determined in the cell culture system for the miR‐196b, which is complementary to 
the NS5A region of the HCV genome and is downregulated in HCV‐infected patients. MiR‐196b 
inhibits HCV replication directly by targeting HCV RNA or indirectly by increasing the expres‐
sion of HMOX1. It has anti‐inflammatory, antioxygenic, and hepatoprotective properties [86].
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Some miRNAs can facilitate HCV lifecycle by targeting host proteins involved in innate 
immunity‐signaling pathways. For example, HCV induced upregulation of miR‐130 blocks 
expression of interferon stimulatory gene IFITM1, which promotes HCV entry into host cells 
[87]. Furthermore, miR‐491 promotes HCV replication through inhibition of the PI3 kinase/
Akt pathway, one of the pathways leading to cancerous properties [80]. Studies analyzing 
circulating miRNA profiles in serum provide novel insights on miRNA expression in HCV 
pathogenesis [88, 89]. In a study by Shwetha et al. [89], it has been shown that the expression 
of miR‐134, miR‐198, miR‐320c, and miR‐483‐5p was upregulated in patients infected with 
HCV 1 and HCV 3 genotypes.
Complex correlation between hepatic expression of abundant liver miRNAs, miR‐122, 
miR‐126, miR‐136, and miR‐181a, and histopathological and clinical characteristic of HCV‐
infected patients has been reported by Boštjančič et al. [31]. The study included liver biopsies 
of patients infected with different genotypes (1, 1a, 1b, 3, and 4) and provided an important 
insight into miRNA expression patterns in different stages and grades of liver disease and 
revealed association among specific miRNA deregulation and patient gender, serum HCV 
viral load, presence of steatosis, and mode of HCV transmission [31].
By contrast, another study by Elhelw et al. [90] has demonstrated upregulation of miR‐181a in 
serum samples of HCV genotype 4‐infected individuals and downregulation in HCV‐infected 
Huh7 cells. In addition, the inverse correlation between miR‐181a serum levels, viral load, 
and liver enzymes was observed. Due to complexity of viral and host factors involved in HCV 
infection and progression to HCV‐induced HCC, multiple clinical parameters should be con‐
sidered and controlled for in the future studies. A systematic approach was recently reported 
by Oliveira et al. [91]. The study evaluated liver and serum expression of miR‐122 in patients 
infected with HCV genotypes 1 and 3 to identify possible associations between miR‐122 
expression and lipid profiles, HCV viral load, apolipoproteins, and liver enzymes [91].
7. MiRNAs as biomarkers in diagnostics and treatment of HBV and HCV
Early diagnosis and treatment of HCC remain challenging due to the lack of early detection meth‐
ods, limited access to diagnosis, expensive medications and the presence of comorbidities, coin‐
fections, and contraindications due to different host and viral factors. Most of HBV‐/HCV‐infected 
individuals remain undiagnosed before they seek medical help due to advanced HCC [10, 92].
The gold standard for the etiology of liver diseases is liver biopsy, an invasive method being 
replaced recently by serological methods and imaging technologies. Current diagnostic tech‐
niques for HCC, which are generally divided into radiological (first‐line diagnostic method 
is ultrasound) and serological methods (serological marker alpha‐fetoprotein, AFP, and des‐
gamma‐carboxy prothrombin), provide limited reliability [93, 94].
7.1. MiRNAs as biomarkers in body fluids
MiRNAs can be detected in various body fluids, such as plasma, serum, urine, and infected 
or diseased tissue and may exhibit host responses to the pathogen or other inflammatory 
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processes; however, miRNA levels in body fluids may not necessarily reflect the miRNA level 
in the infected/diseased tissue, and second, the same miRNA may be upregulated in one 
state of disease and downregulated in another. To provide optimal management of HBV‐ 
and HCV‐related diseases, novel surrogate miRNA biomarkers should be considered [41]. A 
great amount of studies provide promising information on miRNAs as potential diagnostic 
biomarkers of HBV or HCV infection as well as potential diagnostic and treatment tool in 
HBV‐/HCV‐related HCC. According to specific miRNA targets and up‐ or downregulation 
of miRNA expression, potential imitating or antagonistic characteristics of miRNAs could be 
used in HBV‐/HCV‐related therapy.
7.2. HBV miRNA biomarkers
Currently used markers in the diagnostics of HBV can serve as indicators of specific HBV infec‐
tion phases; however, none of them can be used to predict the HBV infection outcome [41].
Several studies suggest that the use of miRNA panels in serum or liver tissue could improve 
the specificity of HBV diagnostics. For example, Li et al. [41] have reported that their 13‐
miRNA‐based biomarker panel could accurately discriminate between HBV cases from 
healthy controls and HCV cases, as well as HBV‐positive HCC cases from healthy controls 
and HBV‐infected patients. The panel of 13 miRNA consisted of the following miRNAs: 
miR‐375, miR‐92a, miR‐10a, miR‐223, miR‐423, miR‐23b/a, miR‐342‐3p, miR‐99a, miR‐122a, 
miR‐125b, miR‐150, and let‐7c [41] (Table 1).
In order to reliably differentiate HCC from chronic HBV infection, cirrhosis, and healthy sub‐
jects, plasma panel of seven miRNAs (miR‐122, miR‐192, miR‐21, miR‐223, miR‐26a, miR‐27a, 
and miR‐801) has been investigated by Zhou et al. [104]. Mizuguchi et al. [107] employed 
sequencing‐based miRNA clustering and showed that the panel of miRNAs was more effec‐
tive for the detection of high‐risk patients for HBV‐related HCC recurrence after liver surgery, 
in comparison to investigation of a single miRNA. MiR‐122, miR‐21, and miR‐34a were identi‐
fied as potential biomarkers for the prediction of HBV‐related HCC.
The miR‐34a is a direct target of the P53 and it has been shown that the expression of miR‐34a 
is downregulated in several human cancers, and when overexpressed, miR‐34a can repress 
several oncogenes and induces apoptosis and arrest of the cell cycle. Deletion of gene region 
encoding miR‐34a has been well detected in breast, lung, cervical, and prostate cancers 
(reviewed by Agostini and Knight [111]). A mimic miR‐34a (MRX34) became a promising 
therapeutic tool for HCC and has reached a clinical trial, phase 1 in 2013 [111].
Individual miRNAs or combination of miRNA and serological markers for HCC have been 
examined and proposed. While an upregulated oncogenic miRNA‐27a has been suggested as 
a therapeutic target in HBV‐related HCC patients [108] and miR‐101 as a potential noninva‐
sive biomarker to differentiate HBV‐related HCC from HBV liver cirrhosis [97, 112], a combi‐
nation of circulating miR‐126 and AFP has been proposed as a promising noninvasive‐specific 
diagnostic biomarker for HBV‐related HCC. Furthermore, combinations of miR‐126/AFP AFP 
and miR‐142‐3p/AFP showed higher efficiency rather than AFP alone in discriminating HCC 
from non‐HCC patients [99].
Importance of MicroRNAs in Hepatitis B and C Diagnostics and Treatment
http://dx.doi.org/10.5772/66498
329
miRNA Deregulation Type of sample Type of method Clinical relevance Reference
miR‐101 Up/down HepG2 and 
HepG2.2.15, HBV‐
HCC tissue, Hep3B, 
and L02, HBVHCC‐
related serum
Microarray, 
qRT‐PCR
Biomarker for 
monitoring the 
progression of tumor 
development in HBV‐
related HCC
Zhang et al. 
[95], Wei et al. 
[96], Fu et al. 
[97]
miR‐106b‐25 
cluster 
(miR‐106b, 
miR‐93, miR‐25)
Up HBV‐infected HCC 
patients
Microarray, 
qRT‐PCR,
Decrease in survival 
time, increase in the 
recurrence rate and 
HCC differentiation in 
HBV‐related HCC
Yen et al. [98]
miR‐122a Up HBV‐infected 
serum, liver tissue of 
HBV‐related HCC
qRT‐PCR, NGS HCC differentiation 
from healthy, chronic 
hepatitis and  
cirrhosis
Li et al. [41]
miR‐126 Up Plasma of HBV 
HCC, liver tissue 
of HCC
Microarray Potential biomarker for 
HBV‐related HCC
Ghosh et al. [99]
miR‐132‐3p Up Plasma of HBV‐
related HCC 
patients
qRT‐PCR Potential biomarker for 
HBV‐related HCC
Wen et al. [100]
miR‐141‐3p Up Serum of HBV‐
related HCC 
patients
NGS, qRT‐PCR Clinical value in 
HBV‐related HCC 
diagnostics
Tan et al. [101]
miR‐142‐3p Up Plasma and liver 
tissue of HBV‐
related HCC
Microarray Potential biomarker for 
HBV‐related HCC
Ghosh et al. [99]
miR‐146a Up/down HepG2 and 
HepG2.2.15, HBV‐
related HCC and 
serum
Microarray 
and Northern 
blotting
Involved in chronicity 
of HBV infection
Liu et al. [75], 
Gui et al. [102], 
Zhang et al. [95]
miR‐146b‐5p Up/down HepG2 and 
HepG2.2.15, HBV‐
related HCC, HBV‐
infected serum
Microarray, 
qRT‐PCR, NGS
Potential research 
interest in chronic HBV 
infections and HBV‐
induced HCC
Hou et al. [47], 
Zhang et al. [95]
miR‐155 Up HepG2, H7402 qRT‐PCR Inhibits HBV infection 
in human hepatoma 
cells
Su et al. [103]
miR‐181a/b Up HepG2 and 
HepG2.2.15
Microarray, 
Northern 
blotting, 
qRT‐PCR
Important role in 
HBV‐induced HCC 
development
Liu et al. [75], 
Zou et al. [76]
miR‐185‐5p Up Plasma of HBV‐
related HCC 
patients
qRT‐PCR Potential biomarker for 
HBV‐related HCC
Wen et al. [100]
miR‐192 Up HBV‐related HCC 
plasma
qRT‐PCR, 
microarray
HCC differentiation 
from healthy, chronic 
hepatitis and cirrhosis
Zhou et al. [104]
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miRNA Deregulation Type of sample Type of method Clinical relevance Reference
miR‐1228‐5p Up Serum of HBV‐
related HCC 
patients
NGS, qRT‐PCR Clinical value in 
HBV‐related HCC 
diagnostics
Tan et al. [101]
miR‐20a/20a‐5p Up/down HepG2 and 
HepG2.2.15, plasma 
of HBV‐related 
HCC
Microarray, 
qRT‐PCR
Potential research 
interest in chronic HBV 
infections and HBV‐
induced HCC
Wen et al. [100], 
Zhang et al. [95]
miR‐21 Up/down HepG2, 
HepG2.2.15, 
Hep3B, HBV‐
related HCC, 
plasma of HBV 
HCC, liver tissue 
of HCC
qRT‐PCR, stem‐
loop RT‐qPCR, 
microarray, 
NGS, clone 
count
HCC differentiation 
from healthy, chronic 
hepatitis and cirrhosis
Hou et al. 
[47], Zhou et 
al. [104], Gao 
et al. [105], 
Bandopadhyay 
et al. [106], 
Ghosh et al. 
[99], Mizuguchi 
et al. [107]
miR‐23a/b Up HBV‐infected 
serum
qRT‐PCR, NGS Biomarker to 
differentiate HBV‐
related HCC from 
controls
Li et al. [41]
miR‐25/25‐3p Up HBV‐infected 
serum, HepG2 and 
HepG2.2.15, plasma 
of HBV‐related 
HCC
qRT‐PCR, 
microarray, 
NGS
Biomarker to 
differentiate HBV‐
related HCC from 
controls
Li et al. [41], 
Zhang et al. 
[95], Wen et al. 
[100]
miR‐27a Up/down HBV‐related HCC, 
HepG2 and Huh7, 
HBV‐related HCC 
plasma
qRT‐PCR, 
microarray
HCC differentiation 
from healthy, chronic 
hepatitis and cirrhosis
Zhou et al. 
[104], Wu et al. 
[108]
miR‐200b Up HepG2, HepG2.2.15 microarray, 
Northern 
blotting
involved in chronicity 
of HBV infection
Liu et al. [75]
miR‐206 Up Serum of HBV‐
related HCC 
patients
NGS, qRT‐PCR Clinical value in 
HBV‐related HCC 
diagnostics
Tan et al. [101]
miR‐221 Up/down HepG2, 
HepG2.2.15, 
Hep3B, HBV‐
related HCC
Microarray, 
Stem‐loop 
RT‐qPCR
Potential research 
interest in chronic HBV 
infections and HBV‐
induced HCC
Gao et al. [105], 
Zhang et al. [95]
miR‐222 Up/down HepG2 and 
HepG2.2.15
Microarray, 
qRT‐PCR
Promotes cell growth 
and migration
Bandopadhyay 
et al. [106], 
Zhang et al., 
2011 [95]
miR‐223 Up/down HBV‐infected 
serum, plasma
qRT‐PCR, 
microarray, 
NGS
HCC differentiation 
from healthy, chronic 
hepatitis and cirrhosis
Zhou et al. 
[104], Li et al. 
[41]
miR‐224 Up/down Hep3B and HepG2 Stem‐loop 
RT‐qPCR
Significantly 
upregulated in HCC
Gao et al. [105], 
Zhang 2011 [95]
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miRNA Deregulation Type of sample Type of method Clinical relevance Reference
miR‐30a‐5p Up Plasma of HBV‐
related HCC
qRT‐PCR Potential biomarker for 
HBV‐related HCC
Wen et al. [100]
miR‐34a Up HBV‐related liver 
samples
NGS, clone 
count
Expressed aberrantly in 
liver cancer
Mizuguchi et al. 
[107]
miR‐320a Up Plasma of HBV 
HCC
qRT‐PCR Potential biomarker for 
HBV‐related HCC
Wen et al. [100]
miR‐324‐3p Up Plasma of HBV 
HCC
qRT‐PCR Potential biomarker for 
HBV‐related HCC
Wen et al. [100]
miR‐342‐3p Up HBV‐infected 
serum
qRT‐PCR, NGS Biomarker for 
differentiation of HBV‐
positive HCC from 
controls
Li et al. [41]
miR‐375 Up HBV‐infected 
serum
qRT‐PCR, NGS Biomarker for 
differentiation of HBV‐
positive HCC from 
controls
Li et al. [41]
miR‐423 Up HBV‐infected 
serum
qRT‐PCR, NGS Biomarker for 
differentiation of HBV‐
positive HCC from 
controls
Li et al. [41]
miR‐433‐3p Up Serum of HBV‐
related HCC 
patients
NGS, qRT‐PCR Clinical value in 
HBV‐related HCC 
diagnostics
Tan et al. [101]
miR‐801 Up HBV‐related HCC 
plasma
qRT‐PCR, 
microarray
HCC differentiation 
from healthy, chronic 
hepatitis and cirrhosis
Zhou et al. [104]
miR‐92a/92a‐3p Up HBV‐infected 
serum, plasma of 
HBV HCC
qRT‐PCR, 
microarray, 
NGS
Potential biomarker for 
HBV‐related HCC
Wen et al. [100], 
Hou et al. [47], 
Li et al. [41]
let‐7f Up HBV‐infected 
serum
qRT‐PCR, NGS Biomarker for 
differentiation of HBV‐
positive HCC from 
controls
Li et al. [41]
miR‐15a Up/down HepG2 and 
HepG2.2.15, plasma 
of HBV‐related 
HCC, liver tissue 
of HCC
Microarray 
and Northern 
blotting
Involved in chronicity 
of HBV infection
Liu et al. [75], 
Ghosh et al. [99]
miR‐18a/b Up/down HepG2 and 
HepG2.2.15, HBV‐
related HCC serum
Microarray, 
NGS, Northern 
blotting, 
qRT‐PCR
Potential research 
interest in chronic HBV 
infections and HBV‐
induced HCC
Zhang et al. 
[95], Li et al. 
[109]
miR‐100 Down HBV‐related HCC qRT‐PCR Important deregulated 
miRNA in HCC
Hou et al. [47]
miR‐106a Down HepG2 and 
HepG2.2.15
Microarray Potential research 
interest in chronic HBV 
infections and HBV‐
induced HCC
Zhang et al. [95]
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miRNA Deregulation Type of sample Type of method Clinical relevance Reference
miR‐122 Down HepG2.2.15, HBV 
infected HCC 
tissue, HBV‐related 
HCC plasma
Microarray, 
qRT‐PCR, NGS, 
clone count
Potential biomarker for 
HCC detection
Zhou et al. [104], 
Li et al. [61], 
Fan et al. [62], 
Mizuguchi et al. 
[107]
miR‐122‐5p Down Serum of HBV‐
related HCC 
patients
NGS, qRT‐PCR Clinical value in 
HBV‐related HCC 
diagnostics
Tan et al. [101]
miR‐125b‐5p Up/down HBV‐related HCC, 
HBV positive 
plasma
qRT‐PCR, 
microarray, 
NGS
Potential biomarker for 
HBV‐related HCC
Hou et al. [47], 
Giray et al. [110]
miR‐143 Down HepG2 and 
HepG2.2.15
qRT‐PCR, 
microarray, 
NGS
Potential research 
interest in chronic HBV 
infections and HBV‐
induced HCC
Hou et al. [47], 
Zhang et al. [95]
miR‐145 Down HepG2, Hep3B. 
HBV‐related HCC, 
HBV‐infected serum
Stem‐loop 
RT‐qPCR
Candidate tumor‐
suppressor miRNA
Gao et al. [105], 
Bandopadhyay 
et al. [106]
miR‐192‐5p Down Serum of HBV‐
related HCC 
patients
NGS, qRT‐PCR Clinical value in 
HBV‐related HCC 
diagnostics
Tan et al. [101]
miR‐199a‐5p Down Serum of HBV‐
related HCC 
patients
NGS, qRT‐PCR Clinical value in 
HBV‐related HCC 
diagnostics
Tan et al. [101], 
Zhang et al. [95]
miR‐199a/b‐3p Down HBV‐related HCC qRT‐PCR, 
microarray, 
NGS
Important deregulated 
miRNA in HCC
Hou et al. [47]
miR‐199b‐5p Down HepG2, 
HepG2.2.15, 
Hep3B. HBV‐
related HCC
miRNA 
microarray, 
Stem‐loop 
RT‐qPCR
Potential research 
interest in chronic HBV 
infections and HBV‐
induced HCC
Gao et al. [105], 
Zhang et al. [95]
miR‐22 Down HepG2 and HBV‐
related HCC
qRT‐PCR Inhibits viral gene 
expression
Shi et al. [71]
miR‐26a Down HBV‐related HCC 
plasma
qRT‐PCR, 
microarray
HCC differentiation 
from healthy, chronic 
hepatitis and cirrhosis
Zhou et al. [104]
miR‐26a‐5p Down Serum of HBV‐
related HCC 
patients
NGS, qRT‐PCR Clinical value in 
HBV‐related HCC 
diagnostics
Tan et al. [101]
miR‐29c Down HBV‐related HCC qRT‐PCR, 
microarray, NGS
Tumor‐ suppressive 
miRNA
Hou et al. [47]
let‐7a/b/c/d Down HBV‐related HCC qRT‐PCR, 
microarray, NGS
Important deregulated 
miRNA in HCC
Hou et al. [47]
Abbreviations: HCC, hepatocellular carcinoma; NGS, next‐generation sequencing; ND, no data available; qRT‐PCR, 
quantitative real‐time polymerase chain reaction.
Table 1. Studies reporting on miRNA deregulation in HBV‐infected patients with HCC or in HBV‐expressing cell lines.
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Serum miRNAs could serve as biomarkers for the detection of liver pathologies [102]. Serum 
HBV‐related miRNAs for HBV‐related HCC diagnosis have been investigated by Tan et al. 
[101]. The study identified eight miRNAs (miR‐206, miR‐141‐3p, miR‐433‐3p, miR‐1228‐5p, 
miR‐199a‐5p, miR‐122‐5p, miR‐192‐5p, and miR‐26a‐5p) and constructed a miRNA set that 
provided high diagnostic accuracy for HBV‐related HCC [101]. The study published by 
Winther et al. [113] presented a panel of circulating plasma miRNAs that are differentially 
expressed in immunological phases of chronically HBV‐infected children and positively cor‐
related with the quantity of HBsAg.
A multicenter study was conducted by Wen et al. [100] to discover a panel of plasma miRNAs 
to discriminate HBV‐related HCC patients from healthy controls. The study revealed that four 
miRNAs (miR‐20a‐5p, miR‐320a, miR‐324‐3p, and miR‐375) (alone or combined with AFP) 
could be used as preclinical biomarkers in HCC screening, while the expression profile of eight 
miRNAs (miR‐20a‐5p, miR‐25‐3p, miR‐30a‐5p, miR‐92a‐3p, miR‐132‐3p, miR‐185‐5p, miR‐
320a, and miR‐324‐3p) can discriminate HCC patients from noncancerous controls [100]. Some 
of the described miRNAs were studied as well by Zhang et al. [95]. MiR‐18a, miR‐125b‐5p, 
and miR‐223‐3p were well described as potential biomarkers for HBV‐related HCC [109, 110].
Hou et al. [47] performed an extensive study of miRNomes in human normal liver, hepati‐
tis liver, and HCC. Researchers presented 15 deregulated miRNAs in 40 HBV‐related HCC 
samples in comparison to healthy controls. Additionally, the consistent decline of miR‐
199a/b‐3p in HCC and its significant correlation with poor prognosis of HCC patients has 
been elucidated, suggesting miR‐199a/b‐3p as a potential HBV therapeutic target. Gao et al. 
[105] investigated the expression of cancer‐related miRNA profiles in early stages of HBV‐
related HCC development and observed altered miRNA expression at various pre‐malignant 
stages of HCC and persistent downregulation of miR‐145 and miR‐199b and upregulation of 
miR‐244 throughout the HCC development. The miR‐145 has been suggested as a candidate 
tumor‐suppressive miRNA due to suppression of cell proliferation caused by overexpression 
of miR‐145 precursor in HepG2 cell lines and abundant expression of miR‐145 in non‐tumor‐
ous livers as well as pre‐malignant low‐grade dysplastic nodules.
Several studies have suggested the role of HBx protein in miRNA expression during HBV infec‐
tion [67, 96, 98, 106]. For example, the recent study, conducted on 120 patients with HBV‐related 
HCC, has shown that the expression of miR‐106b was significantly higher in HBV‐related HCC 
patients in comparison to non‐HBV/non‐HCV‐related HCC patients and suggested that HBx 
enhances miR‐106b transcription and therefore promotes tumor progression in HBV‐related 
HCC [98]. Transfection with the HBx expression plasmid has been recently used in an addi‐
tional study by Yu et al. [114] to investigate HBx‐related regulation of miR‐19a, miR‐122, and 
miR‐223 in malignant hepatocytes. The study has shown that the expression of miRNAs was 
regulated by HBx protein, which enhanced the proliferation of HBx‐transfected HepG2 cells.
7.3. HCV miRNA biomarkers
Apart from a variety of published studies focusing on the identification of HCV infec‐
tion miRNA biomarkers [88], our review focused more on difference in miRNAs profiles 
Advances in Treatment of Hepatitis C and B334
between HCV‐infected cancerous liver cells and HCV‐infected cells without progression to 
HCC. Despite the fact that treatment for most common HCV genotype 1 has been evolving 
rapidly in the past 10 years, no effective and safe anti‐HCV vaccine is available and only 
approximately 50% of patients, infected with HCV genotype 1 (the more common geno‐
type in USA and Western Europe), reach sustained viral response (SVR) while treated with 
most accessible treatment, the interferon. Therefore, the management of HCV‐induced 
liver disease remains problematic [115].
Antagonism of miR‐122 by locked nucleic acid is a promising tool for the treatment of HCV. 
The current most advanced research on miR‐122 antagonist Miravirsen is discussed in the 
following section. Likewise, the therapeutic potential of mimic miR‐196b is presented by 
Kaluzna [30], reviewing studies which confirmed the ability of miR‐196b to inhibit HCV rep‐
lication and revealed that interferon‐induced overexpression of miR‐196b decreases inflam‐
mation and leads to a better response in interferon‐based HCV therapy.
Circulating serum levels of miR‐122 and miR‐222 have been shown to be useful potential 
diagnostic biomarkers for chronic HCV infection in Egyptian patients [116–118], whereas 
in another study miR‐122, miR‐199a, and miR‐16 have been implicated as potential early 
diagnostic biomarkers for HCC in Egyptian patients, chronically infected with HCV [118] 
(Table 2).
Of note, miR‐222 and miR‐224 have been reported to be upregulated in both, HBV and HCV 
infections [95, 105, 116, 121]. However, Bandopadhyay et al. [106] and Zhang et al. [95] reported 
downregulation of miR‐222 and miR‐224 in HBV‐infected patients, respectively. As expres‐
sion profiles of circulating serum biomarkers became a subject of interest in different disease 
studies, serum miRNAs possibly involved in HCV‐related HCC have been investigated in 
several studies. Oksuz et al. [119] examined HCV‐infected patients with chronic infection, 
cirrhosis, and HCC and compared them with control group samples. When all groups of 
samples were compared, the study revealed deregulation of miR‐30c‐5p, miR‐223‐3p, miR‐
302c‐3p, and miR‐17‐5p in cirrhosis and HCC, suggesting possible novel noninvasive bio‐
markers for HCC.
Using whole‐genome expression profiling, Abdalla and Haj‐Ahmad [120] identified 10 
potential HCV‐induced HCC biomarker candidates in urine; five of which were upregu‐
lated in HCC: miR‐335, miR‐618, miR‐625, miR‐532, and miR‐7, and five downregulated: 
miR‐323, miR‐449, miR‐520d, miR‐516‐5p, and miR‐650. The proposed tandem signature 
of downregulated miR‐650 and upregulated miR‐618 showed improved sensitivity and 
specificity for HCC detection, in comparison to the traditional AFP‐level‐based detection 
method.
Increased expression of miR‐155 in hepatocytes of patients infected with HCV has been con‐
firmed in vitro and in vivo by Zhang et al. [85]. In addition, the study revealed that overexpres‐
sion of miR‐155 inhibits apoptosis, and promotes hepatocyte proliferation and tumorigenesis, 
which suggested miR‐155 could be a negative prognostic biomarker for HCC (reviewed 
by Kaluzna [30]). In addition, miR‐155 has been shown to be upregulated in HBV‐infected 
human hepatoma cells, where it inhibits HBV infection [103] (Figure 1).
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MiRNA Deregulation HCV genotype Type of sample Method Clinical relevance Reference
miR‐10a Up ND HCV‐related HCC qRT‐PCR Increased expression in HCV‐
related HCC
Varnholt et al. [84]
miR‐15a Up ND HCV‐related HCC qRT‐PCR Increased expression in HCV‐
related HCC
Varnholt et al. [84]
miR‐16 Up/down ND HCV‐related HCC, 
serum of HCV chronic 
infections
qRT‐PCR, stem loop 
qRT‐PCR
Associated with progression 
of HCC
Varnholt et al. [84], 
El‐Abd et al. [118]
miR‐17‐5p Up ND Plasma of HCV‐related 
HCC
qRT‐PCR Noninvasive biomarker of 
HCV‐positive HCC
Oksuz et al. [119]
miR‐100 Up ND HCV‐related HCC qRT‐PCR Increased expression in HCV‐
related HCC
Varnholt et al. [84]
miR‐122 Up/down ND Serum of HCV patients 
serum of patients with 
chronic HCV infection, 
HCV‐related HCC
RT‐PCR, qRT‐PCR, 
stem loop qRT‐PCR, 
microarray
Detection of HCC in HCV‐
chronic patients
El‐Garem et al. [117], 
Motawi et al. [116], 
El‐Abd et al. [118], 
Varnholt et al. [84]
miR‐125b Up ND HCV‐related HCC qRT‐PCR Increased expression in HCV‐
related HCC
Varnholt et al. [84]
miR‐155 Up ND HCV‐infected patients Stem loop qRT‐PCR Promotes 
hepatocarcinogenesis
Zhang et al. [85]
miR‐192 Up Chimera of 1a/2 Huh7, Huh‐RepSI Microarray Relevant to carcinogenesis Ishida et al. [80]
miR‐194 Up Chimera of 1a/2 Huh7, Huh‐RepSI Microarray Relevant to carcinogenesis Ishida et al. [80]
miR‐200a Up 4 Urine of HCV‐related 
HCC
Microarray, qRT‐PCR Potential HCC biomarker Abdalla et al. [120]
miR‐215 Up Chimera of 1a/2 Huh7, Huh‐RepSI Microarray Relevant to carcinogenesis Ishida et al. [80]
miR‐221 Up ND HCV‐related HCC Microarray Exclusively expressed in 
HCV‐associated HCC
Diaz et al. [121]
miR‐222‐3p Up ND HCV‐related HCC Microarray Exclusively expressed in 
HCV‐associated HCC
Diaz et al. [121]
miR‐224‐3p Up ND HCV‐related HCC Microarray Exclusively expressed in 
HCV‐associated HCC
Diaz et al. [121]
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MiRNA Deregulation HCV genotype Type of sample Method Clinical relevance Reference
miR‐224‐5p Up ND HCV‐related HCC Microarray Exclusively expressed in 
HCV‐associated HCC
Diaz et al. [121]
miR‐299 Up ND HCV‐related HCC qRT‐PCR Increased expression in HCV‐
related HCC
Varnholt et al. [84]
miR‐30c‐5p Up ND Plasma of HCV‐related 
HCC patients
qRT‐PCR Noninvasive biomarker of 
HCV‐positive HCC
Oksuz et al. [119]
miR‐302c‐3p Up ND Plasma of HCV‐related 
HCC patients
qRT‐PCR Noninvasive biomarker of 
HCV‐positive HCC
Oksuz et al. [119]
miR‐326 Up ND HCV‐related HCC 
tumors
qRT‐PCR Increased expression in HCV‐
related HCC
Varnholt et al. [84]
miR‐335 Up 4 Urine of HCV‐related 
HCC patients
Microarray, qRT‐PCR Potential HCC biomarker Abdalla et al. [120]
miR‐370 Up ND HCV‐related HCC qRT‐PCR Increased expression in HCV‐
related HCC
Varnholt et al. [84]
miR‐452 Up ND HCV‐related HCC Microarray Exclusively expressed in 
HCV‐associated HCC
Diaz et al. [121]
miR‐520a* Up 4 Urine of HCV‐related 
HCC patients
Microarray, qRT‐PCR Potential HCC biomarker Abdalla et al. [120]
miR‐521 Up 4 Urine of HCV‐related 
HCC patients
Microarray, qRT‐PCR Potential HCC biomarker Abdalla et al. [120]
miR‐522‐3p Up ND HCV‐related HCC Microarray Exclusively expressed in 
HCV‐associated HCC
Diaz et al. [121]
miR‐532 Up 4 Urine of HCV‐related 
HCC patients
Microarray, qRT‐PCR Potential HCC biomarker Abdalla et al. [120]
miR‐618 Up 4 Urine of HCV‐related 
HCC patients
Microarray, qRT‐PCR miR‐618/650 in tandem to 
detect HCC among HCV‐
positive patients
Abdalla et al. [120]
miR‐625 Up 4 Urine of HCV‐related 
HCC patients
Microarray, qRT‐PCR Potential HCC biomarker Abdalla et al. [120]
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MiRNA Deregulation HCV genotype Type of sample Method Clinical relevance Reference
miR‐640 Up 4 Urine of HCV‐related 
HCC patients
Microarray, qRT‐PCR Potential HCC biomarker Abdalla et al. [120]
miR‐7 Up 4 Urine of HCV‐related 
HCC patients
Microarray, qRT‐PCR Potential HCC biomarker Abdalla et al. [120]
miR‐765 Up 4 Urine of HCV‐related 
HCC patients
Microarray, qRT‐PCR Potential HCC biomarker Abdalla et al. [120]
miR‐9 Up ND HCV‐related HCC qRT‐PCR Increased expression in HCV‐
related HCC
Varnholt et al. [84]
miR‐1269 Up ND HCV‐related HCC Microarray Exclusively expressed in 
HCV‐associated HCC
Diaz et al. [121]
let‐7g Up ND HCV‐related HCC qRT‐PCR Increased expression in HCV‐
related HCC
Varnholt et al. [84]
miR‐16‐5p Down ND HCV‐related HCC Microarray Exclusively expressed in 
HCV‐associated HCC
Diaz et al. [121]
miR‐104 Down ND HCV‐related HCC 
tumors
qRT‐PCR Decreased expression in 
HCV‐related HCC
Varnholt et al. [84]
miR‐106a Down ND HCV‐related HCC 
tumors
qRT‐PCR Decreased expression in 
HCV‐related HCC
Varnholt et al. [84]
miR‐122a Down ND Mainly HCV‐related 
HCC
Microarray Deregulated in HCV‐related 
HCC
Gramantieri et al. 
[122]
miR‐125a‐5p Down ND HCV‐related HCC Microarray Exclusively expressed in 
HCV‐associated HCC
Diaz et al. [121]
miR‐125b‐5p Down ND HCV‐related HCC Microarray Exclusively expressed in 
HCV‐associated HCC
Diaz et al. [121]
miR‐130a Down ND HCV‐related HCC Microarray Exclusively expressed in 
HCV‐associated HCC
Diaz et al. [121]
miR‐134 Down ND HCV‐related HCC 
tumors
qRT‐PCR Decreased expression in 
HCV‐related HCC
Varnholt et al. [84]
miR‐137 Down ND HCV‐related HCC 
tumors
qRT‐PCR Decreased expression in 
HCV‐related HCC
Varnholt et al. [84]
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MiRNA Deregulation HCV genotype Type of sample Method Clinical relevance Reference
miR‐139‐3p Down ND HCV‐related HCC Microarray Exclusively expressed in 
HCV‐associated HCC
Diaz et al. [121]
miR‐139‐5p Down ND HCV‐related HCC Microarray Exclusively expressed in 
HCV‐associated HCC
Diaz et al. [121]
miR‐145 Down ND HCV‐related HCC 
tumors
qRT‐PCR Decreased expression in 
HCV‐related HCC
Varnholt et al. [84]
miR‐147 Down ND HCV‐related HCC 
tumors
qRT‐PCR Decreased expression in 
HCV‐related HCC
Varnholt et al. [84]
miR‐159a Down ND HCV‐related HCC 
tumors
qRT‐PCR Decreased expression in 
HCV‐related HCC
Varnholt et al. [84]
miR‐181a Up/down 4 Huh7, blood, serum liver 
biopsies from chronically 
infected HCV patients
RT‐PCR Disparity in expression 
between serum and liver 
tissue. Upregulation in 
serum‐good prognosis, 
downregulation‐progression 
to HCC
Elhelw et al. [90]
miR‐185 Down ND HCV‐related HCC qRT‐PCR Decreased expression in 
HCV‐related HCC
Varnholt et al. [84]
miR‐195 Down ND HCV‐related HCC Microarray Exclusively expressed in 
HCV‐associated HCC
Diaz et al. [121]
miR‐198 Down ND HCV‐related HCC qRT‐PCR Decreased expression in 
HCV‐related HCC
Varnholt et al. [84]
miR‐199a/‐3p Down ND HCV‐related HCC, 
serum of chronically 
HCV infected
Microarray, qRT‐PCR, 
stem loop qRT‐PCR
Exclusively expressed in 
HCV‐associated HCC
Diaz et al. [121], El‐
Abd et al. [118]
miR‐199a‐5p Down ND HCV‐related HCC Microarray Exclusively expressed in 
HCV‐associated HCC
Diaz et al. [121]
miR‐199b Down ND HCV‐related HCC qRT‐PCR Decreased expression in 
HCV‐related HCC
Varnholt et al. [84]
miR‐199b‐3p Down ND HCV‐related HCC Microarray Exclusively expressed in 
HCV‐associated HCC
Diaz et al. [121]
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MiRNA Deregulation HCV genotype Type of sample Method Clinical relevance Reference
miR‐29c Down ND HCV‐related HCC qRT‐PCR Decreased expression in 
HCV‐related HCC
Varnholt et al. [84]
miR‐204 Down ND HCV‐related HCC qRT‐PCR Decreased expression in 
HCV‐related HCC
Varnholt et al. [84]
miR‐214 Down ND HCV‐related HCC Microarray Exclusively expressed in 
HCV‐associated HCC
Diaz et al. [121]
miR‐218 Down ND HCV‐related HCC qRT‐PCR Decreased expression in 
HCV‐related HCC
Varnholt et al. [84])
miR‐221 Down ND Serum chronic HCV 
patients
RT‐PCR, qRT‐PCR Potential noninvasive 
biomarker for HCV‐related 
HCC
El‐Garem et al. [117]
miR‐223‐3p Down ND Plasma of HCV‐related 
HCC
qRT‐PCR Noninvasive biomarker of 
HCV‐positive HCC
Oksuz et al. [119]
miR‐301a‐3p Down ND HCV‐related HCC Microarray Exclusively expressed in 
HCV‐associated HCC
Diaz et al. [121]
miR‐302b Down ND HCV‐related HCC qRT‐PCR Decreased expression in 
HCV‐related HCC
Varnholt et al. [84]
miR‐320 Down Chimera of 1a/2 Huh7, Huh‐RepSI Microarray Relevant to carcinogenesis Ishida et al. [80]
miR‐323 Down 4 Urine of HCV‐related 
HCC patients
Microarray, qRT‐PCR Potential HCC biomarker Abdalla et al. [120]
miR‐330 Down ND HCV‐related HCC qRT‐PCR Decreased expression in 
HCV‐related HCC
Varnholt et al. [84]
miR‐368 Down ND HCV‐related HCC qRT‐PCR Decreased expression in 
HCV‐related HCC
Varnholt et al. [84]
miR‐424‐3p Down ND HCV‐related HCC Microarray Exclusively expressed in 
HCV‐associated HCC
Diaz et al. [121]
miR‐449 Down 4 Urine of HCV‐related 
HCC patients
Microarray, qRT‐PCR Potential HCC biomarker Abdalla et al. [120]
miR‐491 Down chimera of 1a/2 Huh7, Huh‐RepSI Microarray Relevant to carcinogenesis Ishida et al. [80]
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miR‐497 Down ND HCV‐related HCC Microarray Exclusively expressed in 
HCV‐associated HCC
Diaz et al. [121]
miR‐516‐5p Down 4 Urine of HCV‐related 
HCC patients
Microarray, qRT‐PCR Potential HCC biomarker Abdalla et al. [120]
miR‐520d Down 4 Urine of HCV‐related 
HCC patients
Microarray, qRT‐PCR Potential HCC biomarker Abdalla et al. [120]
miR‐650 Down 4 Urine of HCV‐related 
HCC patients
Microarray, qRT‐PCR miR‐618/650 in tandem to 
detect HCC among HCV‐
positive patients
Abdalla et al. [120]
miR‐761 Down ND HCV‐related HCC Microarray Exclusively expressed in 
HCV‐associated HCC
Diaz et al. [121]
miR‐9* Down ND HCV‐related HCC qRT‐PCR Decreased expression in 
HCV‐related HCC
Varnholt et al. [84]
miR‐95 Down ND HCV‐related HCC qRT‐PCR Decreased expression in 
HCV‐related HCC
Varnholt et al. [84]
let‐7 family Down ND Mainly HCV‐related 
HCC
Microarray Deregulated in HCV‐related 
HCC
Gramantieri et al. 
[122]
Abbreviations: HCC, hepatocellular carcinoma; NGS, next‐generation sequencing; ND, no data available; qRT‐PCR, quantitative real‐time polymerase chain reaction.
* Different mature miRNA from the same stem loop.
Table 2. Studies reporting on miRNA deregulation in HCV‐infected patients with HCC‐ or in HCV‐expressing cell lines.
Importance of MicroRNAs in Hepatitis B and C Diagnostics and Treatment
http://dx.doi.org/10.5772/66498
341
Despite the fact that several studies examined the expression of miRNAs in HCC, discrep‐
ancies exist among published data. Diaz et al. [121] assumed that non‐concordance may be 
the result of differences in selection of noncancerous control samples or commonly included 
HCC samples without prior confirmation of possible HBV or HCV infection. In some previ‐
ous studies, Diaz et al. [121] investigated the expression of miRNAs in HCV‐induced HCC, in 
comparison to a wide range of liver samples and identified 18 miRNAs exclusively expressed 
in HCV‐induced HCC. Several other studies have as well examined subsets of miRNAs 
potentially involved in hepatocellular changes, advancing to HCC [80, 84, 122].
According to an increasing amount of miRNAs identified and examined throughout various 
stages Of HBV/HCV infection and HCC development (Tables 1 and 2), miRNAs not specifically 
presented in this review should be as well included as a subject of interest in future studies.
Figure 1. miRNAs deregulated in HBV‐ and HCV‐related HCC or HBV/HCV‐expression cell lines. miRNAs upregulated 
in HBV and HCV infections are presented in red color, miRNAs downregulated in HBV and HCV infections are 
presented in blue color, while miRNAs that were shown to be up‐ and downregulated in different studies are presented 
in violet color. MiRNAs reported to be up‐ or downregulated in HBV and HCV infections are presented in green color.
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7.4. MiRNA‐122 in HBV and HCV
The levels of liver‐specific miRNA‐122 (miR‐122) are down‐ and upregulated in HBV and 
HCV, respectively. The miR‐122 promotes the replication of HCV and blocks the replication 
of HBV. It has been shown recently that HBV inhibits the miR‐122 expression, suggesting a 
possibility of miR‐122 replacement therapy in HBV‐infected individuals [61, 64]. The study 
by Fan et al. [62] showed that miR‐122 inhibited the expression of the NDRG3 protein, which 
subsequently inhibited malignant cell transformation and presented the miR‐122 and its tar‐
get NDRG3 as key diagnostic markers and potential therapeutic targets in HBV‐related HCC. 
On the other hand, in HCV infections, it has been shown in vitro and in vivo that antagonistic 
utility of miR‐122 inhibits HCV replication cycle and reduces viral load, and thus represents 
an effective treatment of HCV infection. A model of Miravirsen interaction with miR‐122 is 
shown in Figure 2 [77, 123].
Recently, the safety and efficacy of the Miravirsen, a locked nucleic acid form of antisense‐
miR‐122 that sequesters miR‐122, has been evaluated in a phase 2a clinical study, which 
included 36 patients with chronic HCV genotype 1 infection from seven international sites 
[40]. The study observed that treatment with Miravirsen prolonged dose‐dependent reduc‐
tions in HCV RNA, without evidence of viral resistance [40]. Moreover, a recent study, con‐
ducted on 51 HCV‐infected Japanese patients, treated with interferon, presented miR‐122 
as an independent predictor of SVR [124]. Unfortunately, no single miRNA representing a 
promising treatment option in HBV infections has been pointed out as yet.
Nevertheless, therapies that silence HBV RNAs are emerging. Multiple cell‐line‐based stud‐
ies and in vivo studies on mouse models have evaluated synthetically engineered or chemi‐
cally modified small RNAs that complementarily target HBV transcripts and lead to RNA 
degradation and thus to the inhibition of HBV replication. However, due to short duration of 
their activity, the lack of applicable animal model for testing in clinical trials, and subsequent 
Figure 2. Miravirsen interaction with miR‐122 inhibits binding between miR‐122 and the 5′ UTR of the HCV RNA. 
The most abundant liver miRNA‐miRNA‐122 binds with two seed sites in the 5′ UTR of the HCV genome. Miravirsen 
sequesters mature miR‐122 and suppresses HCV.
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pharmacokinetic difficulties, further investigations are warranted to evaluate RNA‐interfer‐
ence‐based approaches to clinical practice (reviewed by Ivacik et al. [125]).
HBV/HCV dual infection is not an uncommon event, occurring in approximately 2–10% of 
chronically infected HCV patients and in 5–20% of chronically infected HBV patients [126]. 
Dual HBV/HCV infection has prognosis of a more aggressive clinical course of liver disease 
than either mono‐infection. Despite the fact that compiling evidence exists on reciprocal inhi‐
bition between HBV and HCV and that miR‐122 represents a crucial host gene involved in 
pathogenesis of both viruses, the role of miR‐122 in HBV/HCV dual infection has not been 
defined so far [127].
8. Conclusion
Cellular miRNAs contribute to HBV and HCV pathogenesis by direct or indirect interac‐
tions with viral genome or proteins and molecules critical for regulation of the cell cycle. 
Regulation of miRNAs expression upon HBV and HCV infection significantly differs between 
both viruses. Reports summarized in this chapter indicate that miRNAs represent an effective, 
noninvasive biomarker tools for early diagnosis of HBV and HCV infection, early diagnosis 
of liver disease and its progressive stages, particularly HCC. Mimic and antagonistic effects 
of cellular miRNAs have been considered in diagnostic and treatment of HBV/HCV‐related 
liver disease, with miR‐122 representing a promising treatment option for chronic infection 
with HCV genotype 1. Because most studies identified and validated miRNAs in heterogenic 
tumors and because miRNA targets were validated mostly in the already‐transformed cell 
culture systems, transfected with plasmids encoding HBV or HCV genome or parts of their 
genome, discrepancies exist in candidate biomarker miRNAs across published studies. Due 
to an extensive number of miRNA targets and other clinical factors considered in significant 
number of studies published in the last 10 years, efforts should be made to establish a spe‐
cific, repetitive, and easy‐to‐operate method to identify reliable panels of miRNA biomarkers 
for early diagnosis and treatment of HBV‐HCV‐related diseases. Suitable reference miRNA 
targets and positive and negative controls should be included in such profiling applications. 
The application of novel techniques such as next‐generation sequencing, development of syn‐
thetic small RNAs, and hepatoma cell lines will impact the subsequent advances in miRNA 
studies related to HBV and HCV pathogenesis as well as miRNA deregulation in other patho‐
logical conditions.
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